Navigation Links
Isis Initates Phase 2/3 Study Of ISIS-TTR Rx And Earns $7.5 Million Milestone Payment From GlaxoSmithKline
Date:2/19/2013

potential and safety of ISIS-TTRRx. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the commercial potential of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2011 and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  KYNAMRO™ is a trademark of Genzyme Corporation.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Edison Pharmaceuticals & Bambino Gesu Childrens Hospital Announce Initiation of EPI-743 Phase 2 Cobalamin C Deficiency Syndrome Clinical Trial
2. Neurim Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of Piromelatine for the Treatment of Insomnia
3. NW Bio Takes Next Steps In Moving Forward With Its Phase III Brain Cancer Trial In Europe
4. Ferring to Highlight Phase 3 Data for Cervical Ripening Candidate at Society for Maternal-Fetal Medicine Annual Meeting
5. RNL BIO filed Phase II/III Clinical Trial with KFDA to Treat Cerebral Palsy Using Autologous Fat Derived Stem Cells
6. Lilly Discontinues Phase 3 Rheumatoid Arthritis Program for Tabalumab Based on Efficacy Results
7. Matrixx Initiatives Withdraws Acquisition Offer for ProPhase Labs
8. Cytos VLP Platform is Basis for Phase 1 Clinical Trial with Anti-IgE Vaccine
9. Vanda Announces Phase IIb/III Clinical Study In Major Depressive Disorder Did Not Meet The Primary Endpoint
10. Targovax AS Announces First Patient Included in Phase I/II Clinical Study With the Therapeutic Cancer Vaccine TG01 in Operable Pancreatic Cancer
11. Cell Therapeutics Announces Data Safety and Monitoring Board Recommendation to Continue the GOG-0212 Phase 3 Clinical Trial of OPAXIOTM as Maintenance Therapy in Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... (NYSE: CVS ) officially announced today that it will rebuild ... fire damage during protests last week.  "As we watched ... past week or so, our hearts turned from pain to the ... Larry Merlo . "Our purpose as a company is helping ... way that we can fulfill that purpose than to reopen our ...
(Date:5/6/2015)... 6, 2015 Fibich, Leebron, Copeland, Briggs & ... settlement has been reached to resolve lawsuits involving individuals ... Actos. Actos - manufactured by Takeda Pharmaceuticals - has ... cancer. Several of the firm,s attorneys were instrumental in ... Tommy Fibich - Founding Partner of Fibich, ...
(Date:5/6/2015)... Research and Markets ( http://www.researchandmarkets.com/research/jskhnb/energy_based ) has ... - Global Strategic Business Report" report to their offering. ... US, Canada , Japan ... , and Rest of World. Annual estimates and forecasts are ... historic analysis is provided for these markets. The ...
Breaking Medicine Technology:CVS Health Announces it Will Rebuild Baltimore CVS/pharmacy Locations 2Takeda Agrees to $2.4 Billion Settlement for Actos Bladder Cancer Lawsuits 2Energy based Ablation Devices - Global Strategic Business Report 2015: Increasing Incidence of Cancer Bodes Well For Energy Based Ablation Devices 2Energy based Ablation Devices - Global Strategic Business Report 2015: Increasing Incidence of Cancer Bodes Well For Energy Based Ablation Devices 3
... 15, 2011 Nephros, Inc. (OTC Bulletin Board: ... marketing filtration products for therapeutic applications, infection control, and ... Inc. effected a one-for-twenty reverse stock split at 5:00 ... by the Financial Industry Regulatory Authority (FINRA) that FINRA ...
... and BALTIMORE, March 15, 2011 ... innovate, implement and commercialize next generation of medical image ... leading clinicians and advanced engineering technologists. ... international communications and information technology company, and Johns Hopkins ...
Cached Medicine Technology:Nephros Announces Split Adjusted Trade Date 2Nephros Announces Split Adjusted Trade Date 3Harris Corporation and Johns Hopkins Medicine Announce Joint Venture to Develop Innovative Medical Image Management Solutions 2
(Date:5/6/2015)... Falls Church, VA (PRWEB) May 07, 2015 ... the Impact of NSF/IPEC/ANSI 363-2014, **FDAnews Webinar**, May ... EDT, http://www.fdanews.com/NewGMPStandards , Most drugs contain ... flow aids, binding agents or other purposes that ... The globalization of the pharma industry, combined with ...
(Date:5/6/2015)... With recent headlines about the kidnapping of Bossini clothing ... from Southern China, it is becoming apparent to people all ... them. This is especially true for High Net Worth Individuals ... through the property they own, the schools their children attend ... individuals, families and companies that are at higher risk than ...
(Date:5/6/2015)... Jersey (PRWEB) May 06, 2015 With ... asthma and subject to its potentially dangerous health effects, ... state-wide program – BEAM (Breathe Easier with Asthma Management) ... The program is being funded through a $500,000 foundation ... Jersey (BGCNJ), which is implementing BEAM throughout the state. ...
(Date:5/6/2015)... As the exclusive hospital of the Tampa Bay Buccaneers, Florida ... Raymond James Stadium for all the “Bucs Babies” celebrating their ... into the “Bucs Babies” program last year. , “It ... particularly those born at the Florida Hospitals here in our ... really enjoyed my time participating in the festivities, interacting with ...
(Date:5/6/2015)... Beach, VA (PRWEB) May 06, 2015 ... and services, today announced it won the Software ... CODiE Award in the "Best Postsecondary Learning Management ... in 2011 and has been finalists for this award ... and innovation that stands out in the industry. ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — New Standards for Excipient GMPs: Analyzing the Impact of NSF/IPEC/ANSI 363-2014 Webinar, May 27, 2015 2Health News:FDAnews Announces — New Standards for Excipient GMPs: Analyzing the Impact of NSF/IPEC/ANSI 363-2014 Webinar, May 27, 2015 3Health News:Pacific Prime China Now Offering Kidnapping & Ransom Insurance 2Health News:The Horizon Foundation for New Jersey and Boys & Girls Clubs in New Jersey Join Forces to Help Children with Asthma 2Health News:The Horizon Foundation for New Jersey and Boys & Girls Clubs in New Jersey Join Forces to Help Children with Asthma 3Health News:The Horizon Foundation for New Jersey and Boys & Girls Clubs in New Jersey Join Forces to Help Children with Asthma 4Health News:Florida Hospital and the Tampa Bay Buccaneers Celebrate “Bucs Babies” Who are Turning One this Month with a Party on the Pirate Ship 2Health News:Florida Hospital and the Tampa Bay Buccaneers Celebrate “Bucs Babies” Who are Turning One this Month with a Party on the Pirate Ship 3Health News:Edvance360 Wins 2015 CODiE Award for Best LMS, Winning Twice and Maintaining Finalist Status for Seven Years Running 2Health News:Edvance360 Wins 2015 CODiE Award for Best LMS, Winning Twice and Maintaining Finalist Status for Seven Years Running 3
... Neurobiological,Technologies, Inc. ("NTI") (Nasdaq: NTII ) today ... by The NASDAQ Stock Market that it has,regained ... Previously, the NASDAQ Listing Qualifications Department had,notified NTI ... $35 million market,value of listed securities continued listing ...
... for Baby Boomers In ... Search of Better Sex, ... during the,holidays that recipients will love. But one product is, in ... ), To view the Multimedia News Release, go to: ...
... November 20 Stora Enso, a leading producer,of ... the first,intelligent pharmaceutical packaging solution to use Cypak,s ... electronic module built,around a single RFID microchip and ... sensors are printed onto the packaging,to detect when ...
... WHO Cuts Global AIDS Estimate by Six Million; AHF Questions Numbers, Seeks ... ... As the World Health,Organization (WHO) prepares to announce a dramatic decrease in ... to 33,million in a report to be released Wednesday, AIDS Healthcare Foundation,(AHF) ...
... MYL ),announced that it completed the sale of 2.14 ... per share and 53.5 million,shares of common stock at ... filed with the Securities and Exchange Commission. The,amounts sold ... underwriters, exercise of the overallotment option. The offerings ...
... Viant, Inc., a leader in,healthcare payment and cost ... as Executive Vice President of Network,Development. Mr. Vangeison ... on delivering quality and value to many of ... Vangeison will have responsibility for all network strategy,including ...
Cached Medicine News:Health News:Give the Gift of Love With Women's Intimacy Product that Increases Pleasure for Both Partners 2Health News:Give the Gift of Love With Women's Intimacy Product that Increases Pleasure for Both Partners 3Health News:Cypak Compliancy Connection Powers Stora Enso Pharma DDSi 2Health News:WHO's New Global AIDS Numbers: 'Let's Stop Guessing,' Says AHF 2Health News:Mylan Completes $2.89 Billion of Equity Financings, Including Exercise of Overallotment Option of Mandatory Convertible Preferred Stock 2Health News:Mylan Completes $2.89 Billion of Equity Financings, Including Exercise of Overallotment Option of Mandatory Convertible Preferred Stock 3Health News:Viant Appoints Keith Vangeison as Executive Vice President of Network Development 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: